US 11,813,197 B2
Ophthalmic lenses and methods for correcting, slowing, reducing, and/or controlling the progression of myopia in conjunction with use of atropine or related compounds
Arthur Back, Danville, CA (US); Padmaja Rajagopal Sankaridurg, Maroubra (AU); and Cathleen Fedtke, Casula (AU)
Assigned to Brien Holden Vision Institute Limited, Sydney (AU)
Filed by Brien Holden Vision Institute Limited, Sydney (AU)
Filed on Dec. 20, 2021, as Appl. No. 17/555,796.
Application 17/555,796 is a continuation of application No. 17/197,858, filed on Mar. 10, 2021, granted, now 11,234,862.
Claims priority of provisional application 63/010,235, filed on Apr. 15, 2020.
Claims priority of provisional application 62/988,225, filed on Mar. 11, 2020.
Prior Publication US 2022/0218520 A1, Jul. 14, 2022
Int. Cl. A61F 9/00 (2006.01); A61K 31/46 (2006.01); G02C 7/04 (2006.01); G02C 7/02 (2006.01); A61F 2/16 (2006.01); A61K 9/00 (2006.01); G02B 21/08 (2006.01)
CPC A61F 9/0017 (2013.01) [A61F 2/1637 (2013.01); A61K 31/46 (2013.01); G02B 21/08 (2013.01); G02C 7/021 (2013.01); G02C 7/022 (2013.01); G02C 7/027 (2013.01); G02C 7/04 (2013.01); A61K 9/0051 (2013.01)] 20 Claims
OG exemplary drawing
 
1. An ophthalmic lens for use in conjunction with a pharmaceutical agent for an eye with myopia, the ophthalmic lens comprising:
a base lens with a front surface and a back surface;
at least one first viewing region having a first power profile, wherein the size of the at least one first viewing region is configured based, at least in part, on the concentration of the pharmaceutical agent; and
one or more myopia control elements with a power profile different than the first power profile, wherein the myopia control elements are shaped as a circular element, ring, annular ring, partial annular ring, arc shaped element, triangular, or spiral or a combination thereof.